Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Dr. Reddy's Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).

The Durezol® brand and generic had U.S. sales of approximately $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA*.

Dr. Reddy's Difluprednate Ophthalmic Emulsion 0.05% is available in 5 ml bottles in case packs of 24.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4204.55 as compared to the previous close of Rs. 4251.80. The total number of shares traded during the day was 6176 in over 1138 trades.

The stock hit an intraday high of Rs. 4299.95 and intraday low of 4176.85. The net turnover during the day was Rs. 25995729.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 Difluprednate OphthalmicEmulsion USMarket Launch